MiMedx Group Statistics
Total Valuation
MiMedx Group has a market cap or net worth of $644.94 million. The enterprise value is $502.76 million.
| Market Cap | 644.94M |
| Enterprise Value | 502.76M |
Important Dates
The next confirmed earnings date is Wednesday, July 29, 2026, after market close.
| Earnings Date | Jul 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MiMedx Group has 148.95 million shares outstanding. The number of shares has increased by 0.31% in one year.
| Current Share Class | 148.95M |
| Shares Outstanding | 148.95M |
| Shares Change (YoY) | +0.31% |
| Shares Change (QoQ) | -1.16% |
| Owned by Insiders (%) | 1.87% |
| Owned by Institutions (%) | 57.92% |
| Float | 117.96M |
Valuation Ratios
The trailing PE ratio is 21.54.
| PE Ratio | 21.54 |
| Forward PE | n/a |
| PS Ratio | 1.66 |
| Forward PS | 2.32 |
| PB Ratio | 2.65 |
| P/TBV Ratio | 3.07 |
| P/FCF Ratio | 9.30 |
| P/OCF Ratio | 9.14 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.51, with an EV/FCF ratio of 7.25.
| EV / Earnings | 16.38 |
| EV / Sales | 1.29 |
| EV / EBITDA | 9.51 |
| EV / EBIT | 12.70 |
| EV / FCF | 7.25 |
Financial Position
The company has a current ratio of 5.39, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.39 |
| Quick Ratio | 4.62 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.32 |
| Debt / FCF | 0.25 |
| Interest Coverage | 23.19 |
Financial Efficiency
Return on equity (ROE) is 13.77% and return on invested capital (ROIC) is 26.87%.
| Return on Equity (ROE) | 13.77% |
| Return on Assets (ROA) | 8.54% |
| Return on Invested Capital (ROIC) | 26.87% |
| Return on Capital Employed (ROCE) | 14.99% |
| Weighted Average Cost of Capital (WACC) | 12.07% |
| Revenue Per Employee | $481,950 |
| Profits Per Employee | $37,989 |
| Employee Count | 808 |
| Asset Turnover | 1.34 |
| Inventory Turnover | 2.94 |
Taxes
In the past 12 months, MiMedx Group has paid $11.62 million in taxes.
| Income Tax | 11.62M |
| Effective Tax Rate | 27.47% |
Stock Price Statistics
The stock price has decreased by -32.55% in the last 52 weeks. The beta is 1.45, so MiMedx Group's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | -32.55% |
| 50-Day Moving Average | 3.80 |
| 200-Day Moving Average | 5.18 |
| Relative Strength Index (RSI) | 65.45 |
| Average Volume (20 Days) | 1,265,189 |
Short Selling Information
The latest short interest is 7.53 million, so 5.05% of the outstanding shares have been sold short.
| Short Interest | 7.53M |
| Short Previous Month | 7.71M |
| Short % of Shares Out | 5.05% |
| Short % of Float | 6.38% |
| Short Ratio (days to cover) | 5.46 |
Income Statement
In the last 12 months, MiMedx Group had revenue of $389.42 million and earned $30.70 million in profits. Earnings per share was $0.20.
| Revenue | 389.42M |
| Gross Profit | 315.59M |
| Operating Income | 39.59M |
| Pretax Income | 42.32M |
| Net Income | 30.70M |
| EBITDA | 52.88M |
| EBIT | 39.59M |
| Earnings Per Share (EPS) | $0.20 |
Balance Sheet
The company has $159.77 million in cash and $17.59 million in debt, with a net cash position of $142.18 million or $0.95 per share.
| Cash & Cash Equivalents | 159.77M |
| Total Debt | 17.59M |
| Net Cash | 142.18M |
| Net Cash Per Share | $0.95 |
| Equity (Book Value) | 242.94M |
| Book Value Per Share | 1.63 |
| Working Capital | 195.78M |
Cash Flow
In the last 12 months, operating cash flow was $70.58 million and capital expenditures -$1.23 million, giving a free cash flow of $69.36 million.
| Operating Cash Flow | 70.58M |
| Capital Expenditures | -1.23M |
| Depreciation & Amortization | 13.30M |
| Net Borrowing | -1.13M |
| Free Cash Flow | 69.36M |
| FCF Per Share | $0.47 |
Margins
Gross margin is 81.04%, with operating and profit margins of 10.17% and 7.88%.
| Gross Margin | 81.04% |
| Operating Margin | 10.17% |
| Pretax Margin | 10.87% |
| Profit Margin | 7.88% |
| EBITDA Margin | 13.58% |
| EBIT Margin | 10.17% |
| FCF Margin | 17.81% |
Dividends & Yields
MiMedx Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.31% |
| Shareholder Yield | -0.31% |
| Earnings Yield | 4.76% |
| FCF Yield | 10.75% |
Analyst Forecast
The average price target for MiMedx Group is $6.60, which is 52.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.60 |
| Price Target Difference | 52.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -6.62% |
| EPS Growth Forecast (3Y) | -23.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MiMedx Group has an Altman Z-Score of 10.88 and a Piotroski F-Score of 6.
| Altman Z-Score | 10.88 |
| Piotroski F-Score | 6 |